Introduction: Psoriasis is a very common chronic inflammatory skin disease affecting up to 3% of the general population with 75% of the psoriasis subjects being affected by a mild form of disease. Hence, topical therapy is the most frequent employed treatment in psoriasis also because it can be easily combined with systemic therapy. In this context, calcipotriol/betamethasone dipropionate (Cal/BD) fixed-dose association represents the first-line treatment due to its efficacy and once-daily application. Different Cal/BD formulations, such as ointment, gel (topical suspension) and aerosol foam, are approved by US Food and Drug Administration. Areas covered: For this review, relevant English literature (trials, real life studies, case series and reviews) regarding Cal/BD different formulations efficacy in psoriasis was searched for through to January 28, 2020. The following database were consulted: PubMed, Embase, The Cochrane Library, Google Scholar, EBSCO, and clinicaltrials.gov. Expert opinion: Cal/BD formulations are efficacious treatment for psoriasis. Cal/BD aerosol foam shows a higher efficacy compared to Cal/BD ointment or gel formulations, appearing as a game changer in psoriasis therapy not only for mild disease but also for moderate psoriasis as well as in selected severe cases in combination with systemic treatments.
File in questo prodotto:
Non ci sono file associati a questo prodotto.